Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

[1]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[2]  L. Silengo,et al.  PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.

[3]  M. Crackower,et al.  The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. , 2004, Journal of molecular and cellular cardiology.

[4]  E. Olson,et al.  Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore , 2004 .

[5]  R. Liao,et al.  Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. , 2004, Journal of Biological Chemistry.

[6]  C. Baylis,et al.  Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat. , 2004, Journal of the American Society of Nephrology : JASN.

[7]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[8]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[9]  D. Kass,et al.  Modulation of In Vivo Cardiac Function by Myocyte-Specific Nitric Oxide Synthase-3 , 2004, Circulation research.

[10]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[11]  E. Olson,et al.  Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.

[12]  C. Deschepper,et al.  Expression of Constitutively Active Guanylate Cyclase in Cardiomyocytes Inhibits the Hypertrophic Effects of Isoproterenol and Aortic Constriction on Mouse Hearts* , 2003, Journal of Biological Chemistry.

[13]  R. Pilz,et al.  This Review Is Part of a Thematic Series on Cyclic Gmp–generating Enzymes and Cyclic Gmp–dependent Signaling, Which Includes the following Articles: Regulation of Nitric Oxide–sensitive Guanylyl Cyclase Cyclic Gmp Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and , 2022 .

[14]  J. Balligand,et al.  Nitric Oxide and Cardiac Function: Ten Years After, and Continuing , 2003, Circulation research.

[15]  J. Beavo,et al.  Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F , 2003 .

[16]  R. Kloner,et al.  Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. , 2003, Circulation.

[17]  J. Kotera,et al.  cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. , 2003, The Biochemical journal.

[18]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[19]  A. Rosenzweig,et al.  Akt and PI 3-Kinase Signaling in Cardiomyocyte Hypertrophy and Survival , 2003, Cell cycle.

[20]  J. Beavo,et al.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain , 2003, The EMBO journal.

[21]  H. Duff,et al.  Time-dependent systolic and diastolic function in mice overexpressing calcineurin. , 2003, American Journal of Physiology. Heart and Circulatory Physiology.

[22]  J. Corbin,et al.  Sildenafil citrate does not affect cardiac contractility in human or dog heart , 2003, Current medical research and opinion.

[23]  Y. S. Kim,et al.  Phosphorylation of glycogen synthase kinase-3β at serine-9 by phospholipase Cγ1 through protein kinase C in rat 3Y1 fibroblasts , 2002, Experimental & Molecular Medicine.

[24]  J. Kotera,et al.  Phosphorylation of Isolated Human Phosphodiesterase-5 Regulatory Domain Induces an Apparent Conformational Change and Increases cGMP Binding Affinity* , 2002, The Journal of Biological Chemistry.

[25]  J. Molkentin,et al.  Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. , 2002, Circulation research.

[26]  N. Yorioka,et al.  A-Kinase Anchoring Protein AKAP220 Binds to Glycogen Synthase Kinase-3β (GSK-3β) and Mediates Protein Kinase A-dependent Inhibition of GSK-3β* , 2002, The Journal of Biological Chemistry.

[27]  C. Kahn,et al.  Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.

[28]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Drexler,et al.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[31]  P. Manow.  ‚The Good, the Bad, and the Ugly‘ , 2002 .

[32]  J. Sadoshima,et al.  Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. , 2002, Circulation Research.

[33]  J. Molkentin,et al.  Impaired cardiac hypertrophic response in Calcineurin Aβ-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Michael D. Schneider,et al.  MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Olson,et al.  Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Trautwein,et al.  Gene Transfer of cGMP-Dependent Protein Kinase I Enhances the Antihypertrophic Effects of Nitric Oxide in Cardiomyocytes , 2002, Hypertension.

[37]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[38]  J. Beavo,et al.  Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance , 2001, Circulation.

[39]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Y. Zou,et al.  Isoproterenol Activates Extracellular Signal–Regulated Protein Kinases in Cardiomyocytes Through Calcineurin , 2001, Circulation.

[41]  E. Marbán,et al.  Mitochondrial ATP-Sensitive Potassium Channels Inhibit Apoptosis Induced by Oxidative Stress in Cardiac Cells , 2001, Circulation research.

[42]  J. Knowles,et al.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.

[43]  D. Garbers,et al.  A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Corbin,et al.  Cyclic nucleotide phosphodiesterases: relating structure and function. , 2001, Progress in nucleic acid research and molecular biology.

[45]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[46]  J. Molkentin,et al.  Calcineurin Promotes Protein Kinase C and c-Jun NH2-terminal Kinase Activation in the Heart , 2000, The Journal of Biological Chemistry.

[47]  G. Condorelli,et al.  Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. , 2000, Circulation research.

[48]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[49]  P. Wright,et al.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[50]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[51]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[52]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.